Drug that cuts risk of breast cancer returning is approved for use in England | Breast cancer

Thousands of women with early breast cancer can be displayed on a drug to stop the return of cancer England.

Up to 4000 patients can be given annually Ribucklik along with hormonal therapyFor early breast cancer for Her2 receptors, despite the initial treatment, despite the risk of a higher return.

Global, One in 20 women will develop breast cancer in her lifeWith the increase of cases by 38 % and deaths by 68 % over the next 25 years, according to the analysis conducted by the International Agency for the search for cancer (IARC).

In the UK, breast cancer rates are expected to rise in the fifth cases to 71,006 a year in 2050, the most common type of breast cancer-which represents about 70 % of cases-positive hormonal tumors and Her2 receptors.

the National Institute for Excellence in the field of care and care (Nice) said that the drug, known under the name of the Kisqali brand, will be available for NHS patients with cancer who have spread to the lymph nodes and at least one of these criteria:

• Cancer is located in at least four of the lymph nodes.

• The cancer in one to three lymph nodes that are either grade 3 (more advanced), or has at least a first tumor 5 cm in size.

RiboCiclib targets the proteins called CDK 4 and CDK 6, which play a role in the growth of cancer cells and division, which helps to slow down or stop the growth of the tumor. It is considered as a 200 mg of a day, along with aromatase inhibitors, a hormone treatment that reduces estrogen levels in the body.

Clinical experiments show that the combination of ribucleib and aromatase inhibitors Time may extend before the cancer is up to 29 %Compared to the use of aromatic inhibitors alone.

Follow the decision Nice approval earlier in April for Capifactep For the treatment of advanced hormone receptors (HR)-HER2 negative breast cancer, which can benefit up to 3,000 women annually.

But some charitable cancer institutions said that they were disappointed with Latifa, who did not agree to the use of ribuciplaib for those who have other forms of early breast cancer at a great risk of repetition.

“We are very anxious that thousands of people with early breast cancer can miss to reach a vital type of treatment due to uncertainty about cost effectiveness,” said Claire Rooney, CEO of Breast Cancer now.

“Despite the promising capabilities of the assistant ribuclelal to reduce the risk of cancer by nearly a third (28.5 %), today’s decision means only some people who suffer from a positive disease of high risk knots, and will not receive anything that suffers from a highly serious negative disease.

“While drug approvals are always welcome, it is disappointing that many people can be deprived of reaching this vital treatment and the opportunity to reduce some concern about the return of cancer.

“Nice and Novartis should work urgently to solve uncertainty about the effectiveness of cost, to ensure a rapid guidance change so that everyone can benefit from the assistant ribosiclike.”